1. Inicio
  2. Publicaciones
  3. Association of statin pre-treatment with baseline stroke severity and outcome in patients with acute ischemic stroke and received reperfusion treatment: An observational study.

Association of statin pre-treatment with baseline stroke severity and outcome in patients with acute ischemic stroke and received reperfusion treatment: An observational study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Matusevicius, Marius
  • Pavia-Nunes, Ana
  • Sevcik, Petr
  • Nevsimalova, Miroslava
  • Rand, Viiu-Marika
  • Kõrv J
  • Cappellari, Manuel
  • Mikulik, Robert
  • Toni, Danilo
  • Ahmed, Niaz

Abstract

BACKGROUND: Statins have an important role in stroke prevention, especially in high-risk populations and may also affect the initial stroke severity and outcomes in patients taking them before an ischemic stroke. AIMS: Our aim was to evaluate the association of statin pre-treatment with the severity in acute ischemic stroke (AIS). METHODS: We analyzed AIS patients received intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT) and recorded in the SITS International Thrombolysis and Thrombectomy Registry from 2011 to 2017. We identified patients with statin information at baseline. The primary outcome was baseline National Institutes of Health Stroke Scale (NIHSS) score. Secondary outcomes were NIHSS score at 24 h, symptomatic intracerebral hemorrhage (SICH) and functional outcome at 90 days after acute intervention. Multivariable linear and logistic regression and propensity score matching (PSM) was used to quantify the effect of statin pre-treatment. RESULTS: Of 93,849 patients, 23,651 (25.2%) were treated with statins prior the AIS. Statin pre-treatment group was older and had higher comorbidity. Median NIHSS at baseline was similar between groups. In the adjusted and PSM analysis, statin pre-treatment was inversely associated with baseline NIHSS (odds ratio (OR) = 0.77, 95% confidence interval (CI) = 0.6-0.99 and OR for PSM 0.73, 95% CI = 0.54-0.99, p = 0.004) and independently associated with mild stroke defined as NIHSS ?8 in adjusted and PSM analysis (OR = 1.21, 95% CI = 1.1-1.34, p < 0.001 and OR for PSM 1.17, 95% CI = 1.05-1.31, p = 0.007). Regarding secondary outcomes, there were no differences in functional outcomes, death nor SICH rates between groups. CONCLUSION: Prior treatment with statins was associated with lower NIHSS at baseline. However, this association did not translate into any difference regarding functional outcome at 90 days. No association was found regarding SICH. These findings indicate the need of further studies to assess the effect on statin pre-treatment on initial stroke severity.

Datos de la publicación

ISSN/ISSNe:
1747-4930, 1747-4949

INTERNATIONAL JOURNAL OF STROKE  SAGE PUBLICATIONS LTD

Tipo:
Article
Páginas:
201-207
PubMed:
35403505
Factor de Impacto:
1,841 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Stroke; lipids; neuroprotection; prevention; severity; statins

Campos de Estudio

Proyectos y Estudios Clínicos

ESTUDIO ALEATORIZADO, DOBLE CIEGO, MULTICÉNTRICO, MULTINACIONAL, CONTROLADO CON PLACEBO, DE SEGURIDAD Y EFICACIA DEL ESCALADA DE DOSIS EN PARALELO ÚNICO DE ACT017 USADO COMO TRATAMIENTO COMPLEMENTARIO POR ENCIMA DEL ESTÁNDAR DE CUIDADO, EN LAS 4,5 HORAS DESPUÉS DE LA APARICIÓN DE LOS SÍNTOMAS DE UN ACCIDENTE CEREBROVASCULAR ISQUÉMICO AGUDO.

Investigador Principal: JOSÉ IGNACIO TEMBL FERRAIRO

ACT-CS-002 . 2019

ESTUDIO INTERNACIONAL DE FASE 2, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE BÚSQUEDA DE DOSIS ADAPTADA A LA RESPUESTA, DE BMS-986177, UN INHIBIDOR DEL FACTOR XIA ORAL, PARA LA PREVENCIÓN DE UN NUEVO CASO DE ICTUS ISQUÉMICO O DE RE-INFARTO CEREBRAL SILENTE EN PACIENTES TRATADOS CON ASPIRINA Y CLOPIDOGREL DESPUÉS DE UN ICTUS ISQUÉMICO AGUDO O UN ACCIDENTE ISQUÉMICO TRANSITORIO (AIT).

Investigador Principal: JOSÉ IGNACIO TEMBL FERRAIRO

CV010031 . 2019

ENSAYO FASE II DE BÚSQUEDA DE DOSIS, MULTICÉNTRICO, ALEATORIZADO, CONTROLADO CON PLACEBO, DOBLE CIEGO Y DE GRUPOS PARALELOS, PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE BAY 2433334 EN PACIENTES DESPUÉS DE UN ICTUS AGUDO ISQUÉMICO NO CARDIOEMBÓLICO

Investigador Principal: JOSÉ IGNACIO TEMBL FERRAIRO

20603 . 2020

EDOXABAN FOR INTRACRANIAL HEMORRHAGE SURVIVORS WITH ATRIAL FIBRILLATION.

Investigador Principal: JOSÉ IGNACIO TEMBL FERRAIRO

ENRICH-AF . 2021

ENSAYO CLÍNICO DOBLE-CIEGO, CONTROLADO CON PLACEBO, ALEATORIZADO, FASE IB/IIA, DE APTOLL PARA EL TRATAMIENTO DE PACIENTES CON ICTUS ISQUÉMICO AGUDO.

Investigador Principal: JOSÉ IGNACIO TEMBL FERRAIRO

APRIL . 2021

Ensayo aleatorizado de optimización hemodinámica de la perfusión cerebral tras tratamiento endovascular en pacientes con ictus isquémico agudo (estudio HOPE).

Investigador Principal: JOSÉ IGNACIO TEMBL FERRAIRO

IIBSP-HOP-2021-21 . 2021

Estudio aleatorizado, multicéntrico y multinacional, con doble enmascaramiento y controlado con placebo, con grupos paralelos, de dosis única y diseño adaptativo para evaluar la eficacia y seguridad del glenzocimab utilizado como tratamiento complementario al tratamiento habitual en las 4,5 horas siguientes a un ictus isquémico agudo.

Investigador Principal: JOSÉ IGNACIO TEMBL FERRAIRO

ACT-CS-005 . 2021

RICORS-ICTUS

Investigador Principal: JUAN BAUTISTA SALOM SANVALERO

RD21/0006/0014 . INSTITUTO DE SALUD CARLOS III . 2022

ENSAYO CLÍNICO ALEATORIZADO MULTICÉNTRICO PARA VALORAR EFICACIA Y SEGURIDAD DE TIROFIBAN VERSUS ASPIRINA INTRAVENOSA EN PACIENTES CON ICTUS ISQUÉMICO AGUDO SECUNDARIO A LESIÓN EN TÁNDEM, SOMETIDOS A TERAPIA DE RECANALIZACIÓN MEDIANTE TRATAMIENTO ENDOVASCULAR.

Investigador Principal: IRENE MARÍA ESCUDERO MARTÍNEZ

ATILA-ictus-2021 . 2022

Cita

Compartir